Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
10,684 results
  • Differential Dynamics Underlying the Gln27Glu Population Variant of the β2-Adrenergic Receptor. [Journal Article]
    J Membr Biol 2019Bhosale S, Nikte SV, … Joshi M
  • The β2-adrenergic receptor (β2AR) is a membrane-bound G-protein-coupled receptor and an important drug target for asthma. Clinical studies report that the population variant Gln27Glu is associated with a differential response to common asthma drugs, such as albuterol, isoproterenol and terbutaline. Interestingly, the 27th amino acid is positioned on the N-terminal region that is the most flexible…
  • Clinical significance of the bronchodilator response in children with severe asthma. [Journal Article]
    Pediatr Pulmonol 2019Coverstone AM, Bacharier LB, … Castro M
  • CONCLUSIONS: Lung function, that is FEV1 % predicted, is a predictor of BD response in children with asthma. Additionally, smoke exposure, higher FeNO or IgE level, and low peripheral blood neutrophils are associated with a greater likelihood of BD reversibility. BD response can identify a phenotype of pediatric asthma associated with low lung function and poor asthma control.
  • Medication-Induced Hyperlactatemia and Lactic Acidosis: A Systematic Review of the Literature. [Review]
    Pharmacotherapy 2019; 39(9):946-963Smith ZR, Horng M, Rech MA
  • Hyperlactatemia and lactic acidosis are two syndromes that are associated with morbidity and mortality. Medication-induced hyperlactatemia and lactic acidosis are diagnoses of exclusion and have the potential to be overlooked. The purposes of this systematic review are to identify published reports of medication-induced lactate level elevations to aid clinicians in diagnosing and comprehending th…
  • Comprehensive Real-World Assessment of Marketed Medications to Guide Parkinson's Drug Discovery. [Journal Article]
    Clin Drug Investig 2019Cepeda MS, Kern DM, … Lovestone S
  • CONCLUSIONS: Armodafinil, modafinil, and methylphenidate were associated with a decreased risk of parkinsonism, as were β-agonists. Of the β-blockers, only propranolol was associated with increased risk. Healthcare database analyses that incorporate scientific rigor provide insight and direction for drug discovery efforts. These findings show association not causality; however, they offer considerable support to the association between β-adrenergic receptor modulation and risk of Parkinson's disease.
New Search Next